Cargando…
Diagnostic Use of Post-therapy (131)I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
(123)I-meta-iodobenzylguanidine ((123)I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. (131)I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy (131)I-mIBG scintigraphy may detect more lesions compared with...
Autores principales: | Wakabayashi, Hiroshi, Kayano, Daiki, Inaki, Anri, Araki, Raita, Kuroda, Rie, Akatani, Norihito, Yamase, Takafumi, Watanabe, Satoru, Hiromasa, Tomo, Kunita, Yuji, Mori, Hiroshi, Saito, Shintaro, Ikawa, Yasuhiro, Fujiki, Toshihiro, Kinuya, Seigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555271/ https://www.ncbi.nlm.nih.gov/pubmed/32887257 http://dx.doi.org/10.3390/diagnostics10090663 |
Ejemplares similares
-
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
por: Inaki, Anri, et al.
Publicado: (2021) -
Utility of (123)I-MIBG Standardized Uptake Value in Patients with Refractory Pheochromocytoma and Paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019) -
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019) -
Author Correction: A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2022) -
Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer
por: Kayano, Daiki, et al.
Publicado: (2013)